传奇生物宣布,其核心产品Carvykti®在截至2026年6月30日的季度中,录得约6.57亿美元的净贸易销售额。这一业绩凸显了该细胞疗法强劲的商业化势头和市场接受度。
传奇生物宣布,其核心产品Carvykti®在截至2026年6月30日的季度中,录得约6.57亿美元的净贸易销售额。这一业绩凸显了该细胞疗法强劲的商业化势头和市场接受度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.